Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 10 studies | 28% ± 14% | |
natural killer cell | 6 studies | 19% ± 4% | |
endothelial cell | 4 studies | 23% ± 6% | |
platelet | 4 studies | 26% ± 3% | |
plasmacytoid dendritic cell | 4 studies | 18% ± 2% | |
fibroblast | 3 studies | 24% ± 6% | |
epithelial cell | 3 studies | 32% ± 3% | |
astrocyte | 3 studies | 33% ± 17% | |
megakaryocyte | 3 studies | 42% ± 15% | |
hematopoietic stem cell | 3 studies | 21% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 3493.07 | 578 / 578 | 100% | 41.10 | 1155 / 1155 |
ovary | 100% | 4200.33 | 180 / 180 | 100% | 29.54 | 430 / 430 |
pancreas | 100% | 2347.52 | 328 / 328 | 100% | 33.58 | 178 / 178 |
uterus | 100% | 4198.18 | 170 / 170 | 100% | 43.84 | 459 / 459 |
skin | 100% | 2646.85 | 1808 / 1809 | 100% | 41.96 | 472 / 472 |
brain | 100% | 3357.54 | 2639 / 2642 | 100% | 42.42 | 705 / 705 |
thymus | 100% | 3047.06 | 653 / 653 | 100% | 35.01 | 604 / 605 |
intestine | 100% | 3185.31 | 966 / 966 | 100% | 29.94 | 526 / 527 |
liver | 100% | 1929.63 | 226 / 226 | 100% | 26.62 | 405 / 406 |
bladder | 100% | 4301.33 | 21 / 21 | 100% | 41.46 | 502 / 504 |
adrenal gland | 100% | 5538.42 | 258 / 258 | 100% | 43.13 | 229 / 230 |
esophagus | 100% | 3067.55 | 1445 / 1445 | 99% | 31.96 | 182 / 183 |
stomach | 100% | 2650.81 | 359 / 359 | 99% | 26.13 | 284 / 286 |
breast | 100% | 3179.26 | 459 / 459 | 99% | 41.76 | 1110 / 1118 |
prostate | 100% | 3939.02 | 245 / 245 | 99% | 31.60 | 498 / 502 |
kidney | 100% | 3085.19 | 89 / 89 | 99% | 25.02 | 890 / 901 |
adipose | 100% | 3091.17 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 39.83 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 57.39 | 29 / 29 |
muscle | 100% | 2992.08 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4574.14 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 34.95 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 37.28 | 1 / 1 |
blood vessel | 100% | 3237.67 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 3087.34 | 854 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 2782.04 | 912 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006561 | Biological process | proline biosynthetic process |
GO_0034599 | Biological process | cellular response to oxidative stress |
GO_0055129 | Biological process | L-proline biosynthetic process |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005739 | Cellular component | mitochondrion |
GO_0005515 | Molecular function | protein binding |
GO_0004735 | Molecular function | pyrroline-5-carboxylate reductase activity |
Gene name | PYCR2 |
Protein name | Pyrroline-5-carboxylate reductase (EC 1.5.1.2) Pyrroline-5-carboxylate reductase 2 (EC 1.5.1.2) Pyrroline-5-carboxylate reductase 2 (P5C reductase 2) (P5CR 2) (EC 1.5.1.2) Pyrroline-5-carboxylate reductase family member 2 isoform 2 Pyrroline-5-carboxylate reductase 2 |
Synonyms | hCG_32783 |
Description | FUNCTION: Housekeeping enzyme that catalyzes the last step in proline biosynthesis. In some cell types, such as erythrocytes, its primary function may be the generation of NADP(+). Can utilize both NAD and NADP. Has higher affinity for NADP, but higher catalytic efficiency with NADH . Involved in cellular response to oxidative stress . . |
Accessions | A0A087WX69 A0A087WZF0 ENST00000489681.5 B3KMB7 ENST00000612039.4 A0A0S2Z5U6 A0A087WTV6 ENST00000472798.2 ENST00000343818.11 A0A0S2Z578 Q96C36 |